Ginkgo Biloba

Phase 3Small molecule

NNational Center for Complementary and Integrative Health (NCCIH)

Ginkgo Biloba is one of 231 small molecule programs targeting Enuresis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

230

Competitors

Pipeline

Status by Indication[3][1]

Indication

EnuresisActive, not recruiting

TinnitusActive, not recruiting

Sexual DysfunctionActive, not recruiting

CognitionActive, not recruiting

Open-Angle GlaucomaActive, not recruiting

MemoryActive, not recruiting

Breast CancerActive, not recruiting

Multiple SclerosisActive, not recruiting

EnuresisPreclinical

Active, not recruiting

TinnitusPreclinical

Active, not recruiting

Sexual DysfunctionPhase 2

Active, not recruiting

CognitionPhase 1

Active, not recruiting

Open-Angle GlaucomaPreclinical

Active, not recruiting

MemoryPhase 1/Phase 2

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

Multiple SclerosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Ginkgo Biloba

NNational Center for Complementary and Integrative Health (NCCIH)

Phase 3

1 2

Halaven

Eisai

Preclinical

38 3

Adriamycin

GGynecologic Oncology Group

Preclinical

87 4

Avastin

Voltaren

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Zinecard

CChildren's Oncology Group

Preclinical

2 8

Aquasol E

NNational Eye Institute (NEI)

Paracetamol

1 10

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Multiple Sclerosis2 trials

Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis

Completed·UUS Department of Veterans Affairs·Phase 2·NCT00841321·120 enrolled

Natural Antioxidants in the Treatment of Multiple Sclerosis

Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 1/2·NCT00010842

Open-Angle Glaucoma2 trials

Ginkgo Biloba and Ocular Blood Flow in Primary Open-angle Glaucoma

Completed·MMaisonneuve-Rosemont Hospital·Phase 2·NCT02376114·19 enrolled

Effect of Ginkgo Biloba Capsule on Visual Function of Primary Open-angle Glaucoma With Blood Stasis Syndrome

Unknown status·ZZhongshan Ophthalmic Center, Sun Yat-sen University·N/A·NCT04334564·512 enrolled

Sexual Dysfunction1 trial

Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction

Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 2·NCT00034021

Breast Cancer1 trial

EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00046891·226 enrolled

Prevention1 trial

Ginkgo Biloba Prevention Trial in Older Individuals

Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 3·NCT00010803·3,069 enrolled

9 more indications

Cognition1 trial

Ginseng and Ginkgo Biloba Effects on Cognition as Modulated by Cardiovascular Reactivity

Completed·—·Phase 1·NCT02386852·48 enrolled

Memory1 trial

Ginkgo Biloba to Improve Short-Term Memory Losses Associated With Electroconvulsive Therapy (ECT)

Terminated·MMedical University of South Carolina·Phase 1/2·NCT00070954·50 enrolled

Efficacy1 trial

The Efficacy of Steroid Therapy in Vestibular Neuritis

Completed·—·Phase 3·NCT02098330·40 enrolled

Alzheimer's Disease1 trial

Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2/3·NCT03090516·240 enrolled

Enuresis1 trial

Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis

Completed·MMenoufia University·N/A·NCT06771128·398 enrolled

Cognitive Function1 trial

Comparison of the Panax Ginseng + Associations to Ginkgo Biloba in the Treatment of Cognitive Function Disorders

Withdrawn·EEMS·Phase 3·NCT01637168

Tinnitus1 trial

Efficacy of Internet and Smartphone Application-delivered Tinnitus Retraining Therapy

Withdrawn·SSeoul National University Hospital·N/A·NCT01663467

Skin1 trial

Effect of Ginkgo Biloba Special Extract LI 1370 on Dual-tasking in Patients With MCI

Completed·UUniversity Hospital, Basel, Switzerland·Phase 4·NCT01046292·50 enrolled

Unspecified1 trial

Effect of Ginkgo Biloba on Phenytoin Elimination

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00011063·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Ginkgo Biloba. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ginkgo Biloba compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ginkgo Biloba. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Center for Complementary and Integrative Health (NCCIH) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNational Center for Complementary and Integrative Health (NCCIH)

Ginkgo Biloba

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Multiple Sclerosis2 trials

Open-Angle Glaucoma2 trials

Sexual Dysfunction1 trial

Breast Cancer1 trial

Prevention1 trial

Cognition1 trial

Memory1 trial

Efficacy1 trial

Alzheimer's Disease1 trial

Enuresis1 trial

Cognitive Function1 trial

Tinnitus1 trial

Skin1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News